ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-PO1031

Microbiome Encoded Enzymes and Mycophenolate Mofetil Enterohepatic Recirculation Parameters in Kidney Transplant Recipients

Session Information

Category: Transplantation

  • 2102 Transplantation: Clinical

Authors

  • Onyeaghala, Guillaume Chinedu, The University of Texas Medical Branch at Galveston, Galveston, Texas, United States
  • Vo, Duy, The University of Texas Medical Branch at Galveston, Galveston, Texas, United States
  • Gupta, Kajal, The University of Texas Medical Branch at Galveston, Galveston, Texas, United States
  • Nguyen, Justin T, The University of Texas Medical Branch at Galveston, Galveston, Texas, United States
  • Mohamed, Moataz, University of Minnesota Twin Cities, Minneapolis, Minnesota, United States
  • Saqr, Abdelrahman, University of Minnesota Twin Cities, Minneapolis, Minnesota, United States
  • Teigen, Levi, University of Minnesota Twin Cities, Minneapolis, Minnesota, United States
  • Dorr, Casey R., University of Minnesota Twin Cities, Minneapolis, Minnesota, United States
  • Staley, Christopher, University of Minnesota Twin Cities, Minneapolis, Minnesota, United States
  • Guan, Weihua, University of Minnesota Twin Cities, Minneapolis, Minnesota, United States
  • Khanipov, Kamil, The University of Texas Medical Branch at Galveston, Galveston, Texas, United States
  • Golovko, George, The University of Texas Medical Branch at Galveston, Galveston, Texas, United States
  • El-Rifai, Rasha, University of Minnesota Twin Cities, Minneapolis, Minnesota, United States
  • Matas, Arthur J., University of Minnesota Twin Cities, Minneapolis, Minnesota, United States
  • Remmel, Rory P., University of Minnesota Twin Cities, Minneapolis, Minnesota, United States
  • Oetting, William S., University of Minnesota Twin Cities, Minneapolis, Minnesota, United States
  • Jacobson, Pamala A., University of Minnesota Twin Cities, Minneapolis, Minnesota, United States
  • Israni, Ajay K., The University of Texas Medical Branch at Galveston, Galveston, Texas, United States
Background

Bacterial β-glucuronidases (βGUS) convert the inactivated mycophenolic acid glucuronide back to the active mycophenolic acid (MPA) through enterohepatic recirculation (EHR), likely enhancing immunosuppression and toxicity in kidney transplant recipients (KTRs). The diversity of these enzymes is not well defined in the microbiome of KTRs. We investigated the association between a sequencing panel of βGUS enzymes and pharmacokinetic (PK) parameters in KTRs.

Methods

Adult KTRs, 35 in prospective cohort (<6 months post-transplant) and 47 in cross-sectional cohort (2+ years post-transplant), underwent a 12hr MPA PK study with stool collection. Microbiome metatranscriptomics were processed with HUMAnN3 and matched against a BLAST panel of 279 βGUS enzymes from the human microbiome clustered gene indices (HMGC). In each cohort, BLAST-derived βGUS transcripts were corrected for the total number of reads and converted to copies per million (cpm) to compare with the Uniref90 database HUMAnN3 output. βGUS transcripts were associated with MPA %EHR (MPA AUC5-12/AUC0-12×100) and the number of EHR peaks during PK using Pearson correlations.

Results

βGUS transcripts were more abundant in HMGC BLAST compared to Uniref HUMAnN3 (mean cpm of 29512 vs 1.78 respectively). We identified 123 unique βGUS enzymes from HMGC. In the prospective cohort, the number of MPA EHR peaks was associated with both MPA EHR (r=0.52, p=0.01) and the relative abundance of βGUS transcripts (r= 0.35, p=0.03) (Table 1). In the cross-sectional cohort, no associations were found with PK or βGUS transcripts.

Conclusion

The relative abundance of βGUS was associated with the number of MPA peaks among KTRs in the early post-transplant period. The number of MPA peaks was also associated with MPA EHR in the same cohort. This suggests that these microbiome-encoded enzymes play a role in MPA variability, captured by the number of PK peaks. Developing in-vitro panels for βGUS enzymes will be necessary elucidate their clinical implications for EHR.

Funding

  • Other NIH Support

Digital Object Identifier (DOI)